# Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

> **NCT00873093** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 148 (actual)

## Conditions studied

- B-cell Adult Acute Lymphoblastic Leukemia
- B-cell Childhood Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Lymphoblastic Lymphoma
- T-cell Adult Acute Lymphoblastic Leukemia
- T-cell Childhood Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** L-asparaginase
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** therapeutic hydrocortisone
- **DRUG:** vincristine sulfate
- **DRUG:** cytarabine
- **DRUG:** prednisone
- **DRUG:** bortezomib
- **DRUG:** pegaspargase
- **DRUG:** methotrexate
- **DRUG:** etoposide phosphate
- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** filgrastim
- **DRUG:** leucovorin calcium
- **OTHER:** laboratory biomarker analysis
- **DRUG:** High Dose MTX

## Key facts

- **NCT ID:** NCT00873093
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2017-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00873093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00873093, "Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00873093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*